<DOC>
	<DOCNO>NCT02075086</DOCNO>
	<brief_summary>A group colorectal cancer ( CRC ) patient treat chemotherapy Bevacizumab ( Bev ) maintain sensitivity progression maintenance treatment remain dependent VEGF angiogenic mediator , patient angiogenic switch ( AS ) become dependent angiogenic cytokine become resistant Bev chemotherapy combination .</brief_summary>
	<brief_title>Angiogenic Switch Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diagnosis stage IV colorectal adenocarcinoma . Age ≥ 18 year . Measurable disease RECIST criterion . Life expectancy ≥ 6 month . Candidate receive treatment firstline chemotherapy . Availability tumor tissue . Patients receive prior treatment firstline chemotherapy metastatic disease . Patients contraindication administration either drug use study : capecitabine , irinotecan , oxaliplatin Bev . Patients receive anticoagulant oral treatment . Patient diagnosis malignancy within 5 year prior diagnosis except basal cell carcinoma cervical carcinoma · situ . · The inclusion patient malignant disease diagnose 5 year ago without recurrence previous 3 year analyze individually Patients bone disease manifestation disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>angiogenic switch</keyword>
	<keyword>plasma cytokine</keyword>
	<keyword>Colon cancer</keyword>
</DOC>